Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | AML: what to look forward to at ASH 2020

Thomas Prebet • 18 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia

Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, outlines what he’s looking forward to at this year’s virtual ASH conference. This includes greater insight into the management of molecularly-defined disease and new agents that are rising as potentially active treatments for acute myeloid leukemia (AML). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.

More from Thomas Prebet

Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
Hypomethylating agent based combinations in MDS
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
New treatments for AML
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020
Treating AML patients who are not eligible for intensive chemotherapy
1:51
Treating AML patients who are not eligible for intensive chemotherapy
Thomas Prebet • 7 Oct 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals